Computational studies with flavonoids and terpenoids as BRPF1 inhibitors: in silico biological activity prediction, molecular docking, molecular dynamics simulations, MM/PBSA calculations

References

• R.L. Siegel, K.D. Miller, H.E. Fuchs, and A. Jemal, Cancer statistics, 2021, CA, Cancer J. Clin. 71 (2021), pp. 7–33. doi:10.3322/caac.21654.
   PubMed Web of Science ®Google Scholar
• J. Zhu, C. Zhou, and A. Caflisch, Structure-based discovery of selective BRPF1 bromodomain inhibitors, Eur. J. Med. Chem. 155 (2018), pp. 337–352. doi:10.1016/j.ejmech.2018.05.037.
   PubMed Web of Science ®Google Scholar
• S.P. Boyson, C. Gao, K. Quinn, J. Boyd, H. Paculova, S. Frietze, and K.C. Glass, Functional roles of bromodomain proteins in cancer, Cancers (Basel) 13 (2021), pp. 3606. doi:10.3390/cancers13143606.
   PubMed Web of Science ®Google Scholar
• S. Gokani and L.K. Bhatt, Bromodomains: A novel target for the anticancer therapy, Eur. J. Pharmacol. 911 (2021), pp. 174523. doi:10.1016/j.ejphar.2021.174523.
   PubMed Web of Science ®Google Scholar
• E.H. Demont, P. Bamborough, C. Chung, P.D. Craggs, D. Fallon, L.J. Gordon, P. Grandi, C.I. Hobbs, J. Hussain, E.J. Jones, A. Le Gall, A.-M. Michon, D.J. Mitchell, R.K. Prinjha, A.D. Roberts, R.J. Sheppard, and R.J. Watson, 1,3-Dimethyl benzimidazolones are potent, selective inhibitors of the BRPF1 bromodomain, ACS Med. Chem. Lett. 5 (2014), pp. 1190–1195. doi:10.1021/ml5002932.
   PubMed Web of Science ®Google Scholar
• C.L.H. Cheng, F.H.C. Tsang, L. Wei, M. Chen, D.W.C. Chin, J. Shen, C.T. Law, D. Lee, C.C.L. Wong, I.O.L. Ng, and C.M. Wong, Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer, Commun. Biol. 4 (2021), pp. 1–14. doi:10.1038/s42003-021-02405-6.
   PubMed Web of Science ®Google Scholar
• J. Cheung, E.N. Gary, K. Shiomi, and T.L. Rosenberry, Structures of human acetylcholinesterase bound to dihydrotanshinone I and territrem B show peripheral site flexibility, ACS Med. Chem. Lett. 4 (2013), pp. 1091–1096. doi:10.1021/ml400304w.
   PubMed Web of Science ®Google Scholar
• S.R. Lin, C.H. Chang, C.F. Hsu, M.J. Tsai, H. Cheng, M.K. Leong, P.J. Sung, J.C. Chen, and C.F. Weng, Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence, Br. J. Pharmacol. 177 (2020), pp. 1409–1423. doi:10.1111/bph.14816.
   PubMed Web of Science ®Google Scholar
• X. Montané, O. Kowalczyk, B. Reig-Vano, A. Bajek, K. Roszkowski, R. Tomczyk, W. Pawliszak, M. Giamberini, A. Mocek-Płóciniak, and B. Tylkowski, Current perspectives of the applications of polyphenols and flavonoids in cancer therapy, Molecules. 25 (2020), pp. 3342. doi:10.3390/molecules25153342.
   Web of Science ®Google Scholar
• B.M.F. Gonçalves, D.S.P. Cardoso, and M.J.U. Ferreira, Overcoming multidrug resistance: Flavonoid and terpenoid nitrogen-containing derivatives as ABC transporter modulators, Molecules. 25 (2020), pp. 3364. doi:10.3390/molecules25153364.
   Web of Science ®Google Scholar
• F. Fontana, M. Raimondi, M. Marzagalli, A. Di Domizio, and P. Limonta, Natural compounds in prostate cancer prevention and treatment: Mechanisms of action and molecular targets, Cells. 9 (2020), pp. 460. doi:10.3390/cells9020460.
   Web of Science ®Google Scholar
• E.R. Sauter, Cancer prevention and treatment using combination therapy with natural compounds, Expert Rev. Clin. Pharmacol. 13 (2020), pp. 265–285. doi:10.1080/17512433.2020.1738218.
   PubMed Web of Science ®Google Scholar
• W.K. Yu, Z.Y. Xu, L. Yuan, S. Mo, B. Xu, X.D. Cheng, and J.J. Qin, Targeting β-catenin signaling by natural products for cancer prevention and therapy, Front. Pharmacol. 11 (2020), pp. 1–12. doi:10.3389/fphar.2020.00984.
   PubMed Web of Science ®Google Scholar
• D. Jones, G.O. Ormondroyd, S.F. Curling, C.-M. Popescu, and M.-C. Popescu. 2 - Chemical Compositions of Natural Fibres, M. Fan and F. Fu, eds., Woodhead Publishing, Sawston, United Kingdom, 2017, pp. 23–58.
   Google Scholar
• R. Li, S.L. Morris-Natschke, and K.-H. Lee, Clerodane diterpenes: Sources, structures, and biological activities, Nat. Prod. Rep. 33 (2016), pp. 1166–1226. doi:10.1039/c5np00137d.
   PubMed Web of Science ®Google Scholar
• A.N. Panche, A.D. Diwan, and S.R. Chandra, Flavonoids: An overview, J. Nutr. Sci. 5 (2016), pp. e47. doi:10.1017/jns.2016.41.
   PubMed Web of Science ®Google Scholar
• D. Luo, J.B. Tong, X.C. Xiao, S. Bian, X. Zhang, J. Wang, and H.Y. Xu, Theoretically exploring selective-binding mechanisms of BRD4 through integrative computational approaches, SAR QSAR Environ. Res. 32 (2021), pp. 985–1011. doi:10.1080/1062936X.2021.1999317.
   PubMed Web of Science ®Google Scholar
• S.L. Wu, J. Zhao, H.B. Sun, H.Y. Li, Y.Y. Yin, and L.L. Zhang, Insights into interaction mechanism of inhibitors E3T, E3H and E3B with CREB binding protein by using molecular dynamics simulations and MM-GBSA calculations, SAR QSAR Environ. Res. 32 (2021), pp. 221–246. doi:10.1080/1062936X.2021.1887351.
   PubMed Web of Science ®Google Scholar
• S.L. Wu, L.F. Wang, H.B. Sun, W. Wang, and Y.X. Yu, Probing molecular mechanism of inhibitor bindings to bromodomain-containing protein 4 based on molecular dynamics simulations and principal component analysis, SAR QSAR Environ. Res. 31 (2020), pp. 547–570. doi:10.1080/1062936X.2020.1777584.
   PubMed Web of Science ®Google Scholar
• L.F. Wang, Y. Wang, Z.Y. Yang, J. Zhao, H.B. Sun, and S.L. Wu, Revealing binding selectivity of inhibitors toward bromodomain-containing proteins 2 and 4 using multiple short molecular dynamics simulations and free energy analyses, SAR QSAR Environ. Res. 31 (2020), pp. 373–398. doi:10.1080/1062936X.2020.1748107.
   PubMed Web of Science ®Google Scholar
• Y. Wang, L.F. Wang, L.L. Zhang, H.B. Sun, and J. Zhao, Molecular mechanism of inhibitor bindings to bromodomain-containing protein 9 explored based on molecular dynamics simulations and calculations of binding free energies, SAR QSAR Environ. Res. 31 (2020), pp. 149–170. doi:10.1080/1062936X.2019.1701075.
   PubMed Web of Science ®Google Scholar
• Y.H. Kim, M. Kim, M. Yoo, J.E. Kim, H.K. Lee, J.N. Heo, C.O. Lee, M. Yoo, K.Y. Jung, C.S. Yun, S.W. Moon, H.K. Chang, C.W. Chung, S. Pyo, S.U. Choi, and C.H. Park, A natural compound, aristoyagonine, is identified as a potent bromodomain inhibitor by mid-throughput screening, Biochem. Biophys. Res. Commun. 503 (2018), pp. 882–887. doi:10.1016/j.bbrc.2018.06.091.
   PubMed Web of Science ®Google Scholar
• F.D. Prieto-Martinez and J.L. Medina-Franco, Charting the bromodomain BRD4: Towards the identification of novel inhibitors with molecular similarity and receptor mapping, Lett. Drug Des. Discov. 15 (2018), pp. 1002–1011. doi:10.2174/1570180814666171121145731.
   Web of Science ®Google Scholar
• J. Li, W. Zou, K. Yu, B. Liu, W. Liang, L. Wang, Y. Lu, Z. Jiang, A. Wang, and J. Zhu, Discovery of the natural product 3’,4’,7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor, J. Enzyme Inhib. Med. Chem. 36 (2021), pp. 903–913. doi:10.1080/14756366.2021.1906663.
   PubMedGoogle Scholar
• I.A. Ramallo, V.L. Alonso, F. Rua, E. Serra, and R.L.E. Furlan, A bioactive Trypanosoma cruzi bromodomain inhibitor from chemically engineered extracts, ACS Comb. Sci. 20 (2018), pp. 220–228. doi:10.1021/acscombsci.7b00172.
   PubMed Web of Science ®Google Scholar
• D.A. Filimonov, A.A. Lagunin, T.A. Gloriozova, A.V. Rudik, D.S. Druzhilovskii, P.V. Pogodin, and V.V. Poroikov, Prediction of the biological activity spectra of organic compounds using the pass online web resource, Chem. Heterocycl. Compd. 50 (2014), pp. 444–457. doi:10.1007/s10593-014-1496-1.
   Web of Science ®Google Scholar
• S. Kim, P.A. Thiessen, E.E. Bolton, J. Chen, G. Fu, A. Gindulyte, L. Han, J. He, S. He, B.A. Shoemaker, J. Wang, B. Yu, J. Zhang, and S.H. Bryant, PubChem substance and compound databases, Nucl. Acids Res. 44 (2016), pp. D1202–D1213. doi:10.1093/nar/gkv951.
   PubMed Web of Science ®Google Scholar
• Discovery studio visualizer. Dassault Systèmes, San Diego, USA, 2019; software available at https://www.3dsbiovia.com/products/collaborative-science/biovia-discovery-studio/visualization-download.php.
   Google Scholar
• O. Trott and A. Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem. 31 (2010), pp. 455–461. doi:10.1002/jcc.21334.
   PubMed Web of Science ®Google Scholar
• T. Gaillard, Evaluation of AutoDock and AutoDock Vina on the CASF-2013 benchmark, J. Chem. Inf. Model. 58 (2018), pp. 1697–1706. doi:10.1021/acs.jcim.8b00312.
   PubMed Web of Science ®Google Scholar
• S.K. Burley, C. Bhikadiya, C. Bi, S. Bittrich, L. Chen, G.V. Crichlow, C.H. Christie, K. Dalenberg, L. Di Costanzo, J.M. Duarte, S. Dutta, Z. Feng, S. Ganesan, D.S. Goodsell, S. Ghosh, R.K. Green, V. Guranović, D. Guzenko, B.P. Hudson, C.L. Lawson, Y. Liang, R. Lowe, H. Namkoong, E. Peisach, I. Persikova, C. Randle, A. Rose, Y. Rose, A. Sali, J. Segura, M. Sekharan, C. Shao, Y.-P. Tao, M. Voigt, J.D. Westbrook, J.Y. Young, C. Zardecki, and M. Zhuravleva, RCSB protein data bank: Powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences, Nucl. Acids Res. 49 (2021), pp. D437–D451. doi:10.1093/nar/gkaa1038.
   PubMed Web of Science ®Google Scholar
• M.Y. Lubula, B.E. Eckenroth, S. Carlson, A. Poplawski, M. Chruszcz, and K.C. Glass, Structural insights into recognition of acetylated histone ligands by the BRPF1 bromodomain, FEBS Lett. 588 (2014), pp. 3844–3854. doi:10.1016/j.febslet.2014.09.028.
   PubMed Web of Science ®Google Scholar
• G.M. Morris, H. Ruth, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem. 30 (2009), pp. 2785–2791. doi:10.1002/jcc.21256.
   PubMed Web of Science ®Google Scholar
• E. Bautista, R.A. Toscano, and A. Ortega, 5,10- seco - neo -clerodanes and neo -clerodanes from Salvia microphylla, J. Nat. Prod. 77 (2014), pp. 1088–1092. doi:10.1021/np4009893.
   PubMed Web of Science ®Google Scholar
• S.Y. Ng, T. Kamada, M. Suleiman, and C.S. Vairappan, A new seco-clerodane-type diterpenoid from Bornean liverwort Schistochila acuminata, Nat. Prod. Commun. 11 (2016), pp. 1071–1072.
   PubMed Web of Science ®Google Scholar
• A. Moulishankar and K. Lakshmanan, Data on molecular docking of naturally occurring flavonoids with biologically important targets, Data Br. 29 (2020), pp. 105243. doi:10.1016/j.dib.2020.105243.
   PubMed Web of Science ®Google Scholar
• J. Rivera-Chávez, C. Bustos-Brito, E. Aguilar-Ramírez, D. Martínez-Otero, L.D. Rosales-Vázquez, A. Dorazco-González, and P. Cano-Sánchez, Hydroxy- neo-clerodanes and 5,10-seco-neo-clerodanes from Salvia decora, J. Nat. Prod. 83 (2020), pp. 2212–2220. doi:10.1021/acs.jnatprod.0c00313.
   PubMed Web of Science ®Google Scholar
• S. Shaker, J. Sang, X.L. Yan, R.Z. Fan, G.H. Tang, Y.K. Xu, and S. Yin, Diterpenoids from Euphorbia royleana reverse P-glycoprotein-mediated multidrug resistance in cancer cells, Phytochemistry. 176 (2020), pp. 112395. doi:10.1016/j.phytochem.2020.112395.
   PubMed Web of Science ®Google Scholar
• F. Aydoğan, E.H. Anouar, M. Aygün, H. Yusufoglu, C. Karaalp, and E. Bedir, An unprecedented diterpene with three new neoclerodanes from Teucrium sandrasicum O. Schwarz, J. Mol. Struct. 1231 (2021), pp. 1–12.
   Web of Science ®Google Scholar
• C. Bustos-Brito, D. Pérez-Juanchi, J. Rivera-Chávez, A.D. Hernández-Herrera, B.Y. Bedolla-García, S. Zamudio, T. Ramírez-Apan, L. Quijano, and B. Esquivel, Clerodane and 5 10-seco-clerodane-type diterpenoids from Salvia involucrata, J. Mol. Struct. 1237 (2021), pp. 130367. doi:10.1016/j.molstruc.2021.130367.
   Web of Science ®Google Scholar
• ACD/ChemSketch, Advanced Chemistry Development Inc., Toronto, Canada, 2001; software available at www.acdlabs.com
   Google Scholar
• D.A. Case, H.M. Aktulga, K. Belfon, I.Y. Ben-Shalom, S.R. Brozell, D.S. Cerutti, T.E. Cheatham, V.W.D. Cruzeiro, T.A. Darden, R.E. Duke, G. Giambasu, M.K. Gilson, H. Gohlke, A.W. Goetz, R. Harris, S. Izadi, S.A. Izmailov, C. Jin, K. Kasavajhala, and P.A. Kollman, Amber 2021, 2021; software available at https://ambermd.org/AmberMD.php
   Google Scholar
• J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollman, and D.A. Case, Development and testing of a general amber force field, J. Comput. Chem. 25 (2004), pp. 1157–1174. doi:10.1002/jcc.20035.
   PubMed Web of Science ®Google Scholar
• D.R. Roe and T.E. Cheatham, PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data, J. Chem. Theory Comput. 9 (2013), pp. 3084–3095. doi:10.1021/ct400341p.
   PubMed Web of Science ®Google Scholar
• S. Genheden and U. Ryde, The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities, Expert Opin. Drug Discov. 10 (2015), pp. 449–461. doi:10.1517/17460441.2015.1032936.
   PubMed Web of Science ®Google Scholar
• S.S. Timur, G. Yalçın, Ö. Çevik, C. Andaç, and R.N. Gürsoy, Molecular dynamics, thermodynamic, and mutational binding studies for tumor-specific LyP-1 in complex with p32, J. Biomol. Struct. Dyn. 1102 (2017), pp. 1–11.
   Google Scholar
• S. Burmaoglu, E.A. Kazancioglu, M.Z. Kazancioglu, R. Sağlamtaş, G. Yalcin, I. Gulcin, and O. Algul, Synthesis, molecular docking and some metabolic enzyme inhibition properties of biphenyl-substituted chalcone derivatives, J. Mol. Struct. 1254 (2022), pp. 132358. doi:10.1016/j.molstruc.2022.132358.
   Web of Science ®Google Scholar
• A.S.A. Manap, A.C.W. Tan, W.H. Leong, A.Y.Y. Chia, S. Vijayabalan, A. Arya, E.H. Wong, F. Rizwan, U. Bindal, S. Koshy, and P. Madhavan, Synergistic effects of curcumin and piperine as potent acetylcholine and amyloidogenic inhibitors with significant neuroprotective activity in sh-sy5y cells via computational molecular modeling and in vitro assay, Front. Aging Neurosci. 10 (2019), pp. 1–17.
   Google Scholar
• M.C. Lee, R. Yang, and Y. Duan, Comparison between generalized-Born and Poisson-Boltzmann methods in physics-based scoring functions for protein structure prediction, J. Mol. Model. 12 (2005), pp. 101–110. doi:10.1007/s00894-005-0013-y.
   PubMed Web of Science ®Google Scholar
• G. Poli, G. Carlotta, F. Rizzolio, and T. Tuccinardi, Application of MM-PBSA methods in virtual screening, Molecules. 25 (2020), pp. 459–494. doi:10.3390/molecules25081971.
   Web of Science ®Google Scholar
• Y.C. Huang, P.C. Lee, J.J. Wang, and Y.C. Hsu, Anticancer effect and mechanism of hydroxygenkwanin in oral squamous cell carcinoma, Front. Oncol. 9 (2019), pp. 1–10.
   PubMed Web of Science ®Google Scholar
• V. Singamaneni, B. Lone, J. Singh, P. Kumar, S. Gairola, S. Singh, and P. Gupta, Coronarin K and L: Two novel labdane diterpenes from Roscoea purpurea: An ayurvedic crude drug, Front. Chem. 9 (2021), pp. 1–7.
   Web of Science ®Google Scholar
• Y. Xia, R. Chen, G. Lu, C. Li, S. Lian, T.W. Kang, and Y. Do Jung, Natural phytochemicals in bladder cancer prevention and therapy, Front. Oncol. 11 (2021), pp. 1–22. doi:10.3389/fonc.2021.652033.
   Web of Science ®Google Scholar
• S.S. Çınaroǧlu and E. Timuçin, Comprehensive evaluation of the MM-GBSA method on bromodomain-inhibitor sets, Brief. Bioinform. 21 (2020), pp. 2112–2125. doi:10.1093/bib/bbz143.
   PubMed Web of Science ®Google Scholar
• W.S. Palmer, Development of small molecule inhibitors of BRPF1 and TRIM24 bromodomains, Drug Discov. Today Technol. 19 (2016), pp. 65–71. doi:10.1016/j.ddtec.2016.06.005.
   PubMedGoogle Scholar